glp 1 drugs medicaid Rhode Island considers ending coverage of GLP-1 for weight loss • Rhode Island Current GLP-1 weight loss medications to

Retatrutide tolerability profile Retatrutide causes more gastrointestinal side effects than mazdutide, which is consistent with its more potent receptor activation profile

Clin J Am Soc Nephrol 12:700710 Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardio

BMJ (Clin

CBC reports Canadians currently pay anywhere from $300 to $500 per month for GLP-1 medications, including semaglutide brands such as Ozempic and Wegovy [Source: cbc.ca/news/health/ozempic-trumprx-cheaper-insurance-9.6970197]

No transdermal GLP-1 patch is FDA approved for weight loss

The pill may appeal to people who are averse to needles, have dexterity limitations that make self-injecting challenging, or who travel or dont have easy access to refrigeration, which the injectables require